Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
The tender explicitly states it is not a public procurement but an open-house model. Legal remedies may be different (s...
No estimated value or volume disclosed; revenue potential is uncertain.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Supply of pharmaceutical products with active substances Cinnarizin and Dimenhydrinat (ATC N07CA22)
- Non-exclusive discount agreements under SGB V §130a Abs. 8
Show full summary
This is an open-house model for non-exclusive discount agreements on pharmaceutical products Cinnarizin and Dimenhydrinat (ATC N07CA22) with AOK Bayern. It is not a competitive procurement; any qualified pharmaceutical company may enter into identical, non-negotiable discount agreements. The contract term runs from 01.06.2025 to 31.05.2027, with possible termination. Submission is either in paper form (two copies) or electronically with a qualified electronic signature. Eligibility is limited to pharmaceutical companies that submit a signed declaration of reliability. No estimated value, award criteria, or competitive selection is involved.
Risks
The tender explicitly states it is not a public procurement but an open-house model. Legal remedies may be different (s...
No estimated value or volume disclosed; revenue potential is uncertain.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible
Administrative
- Must submit a signed declaration of reliability
- Contract must be submitted in two paper copies or electronically with qualified electronic signature
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Non-exclusive discount agreements for pharmaceutical products containing the active substances Cinnarizin and Dimenhydrinat (ATC N07CA22). All qualified pharmaceutical companies may join.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 248752-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
The tender explicitly states it is not a public procurement but an open-house model. Legal remedies may be different (s...
No estimated value or volume disclosed; revenue potential is uncertain.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications